Abstract:Purpose/Objective(s) To identify clinical and dosimetric factors associated with the radiation-induced rib fracture (RIRF) after stereotactic body radiotherapy (SBRT), and to provide more appropriate ribs dose constraints. Materials/Methods Patients treated with SBRT for primary or metastatic lung tumors within 1 cm from Ribs, and had no previous overlapping radiation exposure were eligible to this study. Clinical factors, rib bone mineral density (BMD) and dosimetric parameters were evaluated for their associations with RIRFs. All cases were reviewed by experienced radiologists to detect and grade RIRF using the radiological as well as clinical toxicity data, as per CTCAE v5.0. Variable filtering was done through the least absolute shrinkage and selection operator (Lasso). A dose-event curve and predictive model were created. Calibration Curves were used to evaluate model prediction accuracy. Results A total of 160 patients with 165 lesions were eligible. After a median follow-up of 26.2 months (range: 10.5 – 62.6), 46 RIRFs were detected (27.9%) , including 20(42.6%) Grade 1 RIRFs, 25(53.2%) Grade 2 RIRFs and only 1 Grade 3 RIRF. The median interval from SBRT to RIRF detection was 16 months (range: 6.33-45.30). Of the 68 fractured ribs, 52 (76.5%) developed in ribs 2-5. 3 optimal dosimetric parameters and 1 optimal rib BMD parameter were filtered from 82 dosimetric parameters and 12 rib BMD parameters. As these three dosimetric parameters were cross-correlated, we selected Rib-BED3D1.4cc as the representative dosimetric predictor, who's cut-off value (α/β=3, LQ-model, Rib-BED3D1.4cc=212.16Gy) was extraordinarily higher than the AAPM Task Group 101 dose constrains for ribs (Rib-BED3D1cc<120.96Gy for 3 fractions, 116.67Gy for 5 fractions). Multivariate analysis showed that the rib location of the maximum dose point (Dmax Rib, odds ratio:21.491, p=0.018), mean density of the rib cortex (Cortex mean, odds ratio: 0.995, p = 0.018) and Rib-BED3D1.4cc (odds ratio: 1.013, p = 0.004) were all significantly associated with the RIRF. The final predictive logistic model for RIRFs included Dmax Rib, Cortex mean and Rib-BED3D1.4cc had significantly better predictive ability than any of the dosimetric predictor alone (AUC 0.791 vs 0.701, p = 0.0336). A nomogram was constructed based on the logistic model. Conclusion This study developed and validated a comprehensive model integrating rib BMD parameters with dosimetric factors to predict RIRFs. A predictive nomogram of AUC of 0.79 may provide an opportunity to guide clinicians. For the dosimetric predictor alone, we suggest that Rib-BED3D1.4cc less than 212.16Gy would be more appropriate.

Predicting radiation‐induced immune suppression in lung cancer patients treated with stereotactic body radiation therapy

Inflammation Index Predicts Radiation-Induced Lung Injury and Prognosis in Lung Tumors Treated with Stereotactic Body Radiation Therapy

Development and Validation of a Risk-Prediction Model for Immune-Related Adverse Events in Patients with Non-Small-cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors.

Predicting Severe Radiation Pneumonitis in Patients with Locally- Advanced Non-Small Cell Lung Cancer after Thoracic Radiotherapy: Development and Internal Validation of a Nomogram Based on the Clinical, Hematological and Dose–volume Histogram Parameters

Development and validation of a lung biological equivalent dose-based multiregional radiomic model for predicting symptomatic radiation pneumonitis after SBRT in lung cancer patients

Prognosis And Risk Factors Of Radiation-Induced Lymphopenia In Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy

Quantitative analysis of interstitial lung abnormalities on computed tomography to predict symptomatic radiation pneumonitis after lung stereotactic body radiotherapy

Radiomics-Based Predictive Model of Radiation-Induced Liver Disease in Hepatocellular Carcinoma Patients Receiving Stereo-Tactic Body Radiotherapy

Predicting Regional Recurrence and Prognosis in Stereotactic Body Radiation Therapy-Treated Clinical Stage I Non-small Cell Lung Cancer Using a Radiomics Model Constructed with Surgical Data

Developing a prediction model for radiation pneumonitis in lung cancer patients treated with stereotactic body radiation therapy combined with clinical, dosimetric factors and laboratory biomarkers

Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging

Predictive Model for the Radiotherapy Induced Rib Fracture (RIRF) after Stereotactic Body Radiotherapy

Early lymphocyte levels and low doses radiation exposure of lung predict lymphopenia in radiotherapy for lung cancer

A novel predictor for dosimetry data of lung and the radiation pneumonitis incidence prior to SBRT in lung cancer patients

Clinical Translation of a Deep Learning Model of Radiation-Induced Lymphopenia for Esophageal Cancer

Radiation Pneumonitis Prediction after Stereotactic Body Radiation Therapy Based on 3D Dose Distribution: Dosiomics And/or Deep Learning-Based Radiomics Features

The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy

Shortened Radiation Time Promotes Recovery from Radiation-induced Lymphopenia in Early-Stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy.

Development and Validation of a Random Forest Model for Predicting Radiation Pneumonitis in Lung Cancer Patients Receiving Moderately Hypofractionated Radiotherapy: a Retrospective Cohort Study

Systemic Inflammation-Immune Status Score Predicts the Incidence of Radiation Induced Pneumonitis in Patients with Breast Cancer after Whole Breast Irradiation: A Result from Two Medical Centers

Real-world Decision-making Process for Stereotactic Body Radiotherapy Versus Minimally Invasive Surgery in Early-stage Lung Cancer Patients